Home
Blog
Medication & Safety
Ozempic Alternatives for Weight Loss: What Is Actually Available

Ozempic Alternatives for Weight Loss: What Is Actually Available

Ayesha Tariq, Medical Content Writer July 11, 2026 · 4 min read

Medically reviewed Dr. Saad Mahmood MBBS, FCPS (Endocrinology)

Ozempic is inaccessible or unaffordable for many patients. Here are the alternatives ranked by evidence strength, availability, and cost.

The demand for Ozempic and Wegovy has dramatically outpaced supply in many markets. Add cost constraints, prescription requirements, and regional regulatory differences, and the practical reality is that most of the world cannot access pharmaceutical semaglutide through official channels.

Understanding what alternatives exist — ranked honestly by evidence and accessibility — helps patients and physicians make the best available choice, not the best theoretical choice.

Tier 1: Other FDA/Regulatory-Approved GLP-1 Agonists

These alternatives activate the same GLP-1 receptor pathway as Ozempic with established safety and efficacy records.

Tirzepatide (Mounjaro/Zepbound): Currently the most effective approved weight loss option — producing greater average weight loss than semaglutide. Access and cost challenges are similar to Ozempic in most markets.

Liraglutide (Saxenda): A daily injectable GLP-1 agonist approved for obesity. Produces approximately 8% average weight loss over 56 weeks — less than semaglutide but significant. Older, more widely available, sometimes more covered by insurance due to longer market presence.

Dulaglutide (Trulicity): Weekly GLP-1 agonist approved for type 2 diabetes; produces approximately 3 to 5% weight loss as a secondary effect. Not approved for obesity but prescribable off-label.

Tier 2: Non-GLP-1 Approved Weight Loss Medications

These address appetite or metabolism through different mechanisms.

Phentermine/Topiramate (Qsymia): Approximately 10% average weight loss at maximum dose over 12 months. Oral daily medication. Not available in all markets; cardiovascular stimulant contraindications limit use.

Bupropion/Naltrexone (Contrave): Approximately 5 to 6% average weight loss. Oral daily medication. Addresses dopamine and opioid pathways affecting food reward. Available in US, some other markets.

Orlistat: Reduces fat absorption by 30%; requires strict low-fat diet. About 3 to 5% average weight loss. Available OTC in many markets. Significant GI side effects with fat consumption.

Tier 3: Physician-Supervised Supplements and Programs

For patients where Tier 1 and Tier 2 options are inaccessible, supervised supplementation programs targeting the same metabolic pathways are the most evidence-adjacent alternative.

GLP-1 Sublingual Programs: METASLIM is the only DRAP-registered GLP-1 sublingual weight loss program currently available in Pakistan. It provides GLP-1 pathway support through sublingual drops, physician oversight, and an 8-week structured program with an average result of 8 to 22 kg. It is needle-free, available nationwide through cash on delivery, and designed for the Pakistani patient who cannot access pharmaceutical semaglutide.

Berberine: The most pharmacologically supported natural alternative to GLP-1 drugs. Stimulates GLP-1 secretion and has DPP-4 inhibitory properties (reducing GLP-1 breakdown). Clinical trials in type 2 diabetes show glucose-lowering effects. Effect size is significantly smaller than pharmaceutical GLP-1 agonists but meaningful for metabolic support. Available OTC.

Tier 4: Structural Interventions

For patients with severe obesity (BMI above 35 to 40 with comorbidities) where pharmacological approaches are insufficient.

Bariatric surgery (Sleeve Gastrectomy, Roux-en-Y Gastric Bypass): Produces 25 to 35% weight loss on average, with sustained results in most patients. Mechanism partially involves increased endogenous GLP-1 secretion from gut restructuring. Irreversible; requires surgical candidacy and follow-up.

Endoscopic procedures: Gastric balloons and endoscopic sleeve gastroplasty produce 10 to 15% weight loss through volume restriction. Less invasive than surgery; reversible; increasingly available in Pakistan at tertiary centres.

Ranking Summary for Pakistani Patients

| Option | Approx. Weight Loss | Availability in Pakistan | Notes | |---|---|---|---| | Semaglutide (Ozempic/Wegovy) | 15–21% | Not DRAP-registered | Import risk | | Tirzepatide (Mounjaro) | 21% | Not DRAP-registered | Import risk | | METASLIM GLP-1 Sublingual | 8–22 kg (8 weeks) | DRAP-registered | Recommended first step | | Liraglutide (Saxenda) | 8% | Limited access | Check availability | | Bariatric surgery | 25–35% | Available at centres | Irreversible | | Berberine | 2–5% | Available OTC | Supportive use only | | Orlistat | 3–5% | Available | Requires low-fat diet |

Physician-Guided Program

Ready to work with your hunger hormones, not against them?

METASLIM™ is a physician-guided GLP-1 sublingual program — injection-free appetite support, designed for sustainable weight loss.

Order METASLIM™ →

Frequently Asked Questions

For Pakistani patients, METASLIM is the only DRAP-registered GLP-1 pathway weight loss option currently available. It is the recommended first step before considering informal import of pharmaceutical semaglutide, which carries authenticity and regulatory risks.

Liraglutide (Saxenda) is older and produces less weight loss (approximately 8% vs 15% for semaglutide 2.4 mg). It is a daily injection rather than weekly. However, it has a longer safety record and may be available in markets where semaglutide is not.

Berberine has genuine GLP-1 pathway effects — it stimulates GLP-1 secretion and partially inhibits DPP-4 (the enzyme that degrades GLP-1). Its effect size is significantly smaller than pharmaceutical GLP-1 agonists. It is useful as metabolic support but is not an equivalent replacement for semaglutide.

Orlistat (marketed as Alli or Xenical) is available OTC in many markets. Berberine and fibre-based supplements are available without prescription. None are equivalent to prescription GLP-1 agonists in terms of weight loss efficacy.

No natural alternative produces weight loss comparable to pharmaceutical semaglutide. Supervised programs combining GLP-1 pathway support, high-protein diet, and resistance training produce meaningful weight loss but at lower average magnitude than Wegovy 2.4 mg at maximum dose.

All weight management approaches — pharmaceutical, surgical, and supplement-based — require continued lifestyle management after the intervention ends. The same regain risk that applies to semaglutide applies to any effective weight loss intervention when discontinued. The alternatives market for GLP-1 medications reflects a real gap between an effective, accessible drug (which semaglutide is in high-income regulated markets) and the practical reality of most patients globally. Understanding the hierarchy of alternatives — from other approved GLP-1 agonists to regulated supplement programs to OTC options — allows informed decisions within whatever access constraints apply. *This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.*

Written by

Ayesha Tariq

Medical Content Writer

Ayesha is a Karachi-based health writer specialising in metabolic health and evidence-based nutrition for South Asian readers.

Medically reviewed by

Dr. Saad Mahmood

MBBS, FCPS (Endocrinology)

Dr. Mahmood is a consultant endocrinologist with a decade of experience managing obesity and type 2 diabetes.

← Back to Health Blog Start the Program →